Vertex Telaprevir NDA In Treatment-Naive Hep C Now Planned For 2010
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryVertex Pharmaceuticals expects to have data available from Phase III trials evaluating the protease inhibitor telaprevir in patients with hepatitis C by mid-2010, the company announced Jan. 23. The program was initiated in March
You may also be interested in...
The company said it will update investors on the path forward for zuranolone in major depressive disorder after finalizing discussions with the US FDA. It would not confirm if a meeting had taken place yet.